DBP International AB: Japanese patent for Temodex / SI-053 is granted
Double Bond Pharmaceutical International AB (publ) ("DBP" or "The Company", org. No. 556991-6082) has today, February 11th 2022, received information about the granting of a Japanese patent application concerning the company's front-line product Temodex / SI-053. Patent approval provides protection for the technology and the product in Japan until at least 2036. "This is a very important milestone in the development of SI-053 as Japan is one of the biggest markets where we plan to expand the global commercialization of the product," comments Igor Lokot, CEO of DBP. – “We also have